Nephros (NASDAQ:NEPH) Research Coverage Started at Northland Securities

Northland Securities started coverage on shares of Nephros (NASDAQ:NEPH) in a research report sent to investors on Friday, MarketBeat Ratings reports. The firm issued a market perform rating and a $4.00 price target on the stock.

Separately, Weiss Ratings raised Nephros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, June 18th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $5.00.

Nephros Price Performance

NEPH stock opened at $3.78 on Friday. The company’s 50 day simple moving average is $3.45 and its 200-day simple moving average is $3.64. The firm has a market capitalization of $41.05 million, a PE ratio of 54.01 and a beta of 1.49. Nephros has a 12 month low of $2.66 and a 12 month high of $6.42.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. Nephros had a net margin of 4.06% and a return on equity of 7.66%. The business had revenue of $5.21 million during the quarter, compared to analysts’ expectations of $5.02 million.

Institutional Investors Weigh In On Nephros

Hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new position in Nephros in the fourth quarter valued at $29,000. Dimensional Fund Advisors LP boosted its stake in Nephros by 52.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock worth $62,000 after buying an additional 7,144 shares during the last quarter. Heron Bay Capital Management purchased a new stake in Nephros in the 4th quarter valued at about $66,000. Citadel Advisors LLC grew its holdings in Nephros by 39.2% in the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after buying an additional 4,655 shares during the period. Finally, XTX Topco Ltd increased its stake in shares of Nephros by 48.5% during the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock valued at $105,000 after acquiring an additional 7,062 shares during the last quarter. Hedge funds and other institutional investors own 41.10% of the company’s stock.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.